Clinical trials sponsored by Shanghai Changzheng Hospital

Phase breakdown

Conditions studied

Recruiting trials led by Shanghai Changzheng Hospital

• A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α SrRNA in Treating Metastatic CRC Patients
  NCT06621173 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer
  NCT07050394 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
  NCT07398326 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer
  NCT05585814 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens
  NCT07043166 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Efficacy and Safety of Rifaximin in Treating MAFLD
  NCT07185932 · Phase: Early Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Fecal Microbiota Transplantation for Obese Women With Polyendocrine Metabolic Ovarian Syndrome
  NCT07746635 · Phase: Not applicable (e.g. observational or device study) · Ages: 20 Years to 40 Years · Sex: Female · 1 location
• HiSCs in the Treatment of Rheumatoid Arthritis
  NCT06947746 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer
  NCT06603376 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• MTS109 in Patients With Refractory Autoimmune Diseases
  NCT07526350 · Phase: Early Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Pancreatic Cancer and Diabetes Mellitus
  NCT06585072 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.
  NCT06930118 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials is Shanghai Changzheng Hospital recruiting for?

Shanghai Changzheng Hospital is the lead sponsor of 12 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.